Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

Fiona Powrie receives an Honorary Lifetime Membership of the British Society for Immunology at the BSI Congress
Fiona Powrie receives an Honorary Lifetime Membership of the British Society for Immunology at the BSI Congress

Fiona Powrie, Director of the Kennedy Institute was awarded honorary membership in recognition of her contributions to the field of immunology, including her seminal work on regulatory T cells and pioneering gut immunology research. The awards were announced at the recent British Society for Immunology Congress held in Edinburgh.

Professors Dame Sarah Gilbert, Teresa Lambe, and Sir Andrew Pollard received the awards for developing the ChAdOx1 nCoV-19 coronavirus vaccine, and all four have inspired scores of new immunologists in the field.

Fiona said: 'As an immunologist it is particularly special to be recognised by my colleagues with Lifetime Membership of the British Society for Immunology. I have been a member of the BSI since I started my training and benefited then from the science and networking opportunities as do members of my lab today.'

Professors Gilbert, Lambe and Pollard also accepted the Global Impact and Innovation Award in recognition of all those involved in the design and development of the ChAdOx1 nCoV-19, including the scientists, support staff and clinical trial volunteers.

Professor Teresa Lambe OBE, Head of Vaccine Immunology at the Oxford Vaccine Group, said: 'It is an honour to be recognised with this award from my fellow immunologists, but in particular I was humbled to accept the award on behalf of the teams who have worked across the ChAdOx1 nCoV-19 vaccine development here at Oxford, whose efforts have been integral to seeing this vaccine developed in record time, with over 2 billion doses now released worldwide.'

 

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.